Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 46,549

Document Document Title
WO/2014/081764A1
The present invention provides non-human animal models of neuronal injury and/or cognitive dysfunction and methods of making and using such animal models. The animal models of the invention are particularly suited to assessing neurodegen...  
WO/2014/081439A1
A method for inducing autophagy in a subject having an autophagy defect is provided. The method of the present invention includes the step of administering to the subject a therapeutically effective amount of a Ganoderma lucidum extract,...  
WO/2014/079850A1
The present invention relates to compounds of general formula (I-1) or (I-2) wherein R1 is hydrogen, lower alkyl, lower alkoxy, halogen, O(CH2)2-lower akoxy, O(CH2)2N(CH3)2, or O(CH2)-morpholinyl; R1' is hydrogen, lower alkyl, lower alko...  
WO/2014/081675A1
The present invention provides methods and compositions for treating neurodegenerative diseases by cyclohexenone compounds.  
WO/2014/078378A1
Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH...  
WO/2014/078328A1
Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment ...  
WO/2014/078408A1
Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of ...  
WO/2014/075309A1
Provided in the present invention are the use of compounds having the structure of general formula (I) and medicinal salts, hydrates or solvates thereof in the preparation of drugs for treating nervous system diseases associated with dop...  
WO/2014/077365A1
The present application provides: Lactobacillus gasseri strain CP2305 (FERM BP-11331), Lactobacillus gasseri strain CP2305s (NITE BP-1405), or a variant strain (e.g., a psychrotolerant variant strain) of Lactobacillus gasseri strain CP23...  
WO/2014/075203A8
The invention relates to a novel pharmaceutical formulation comprising polymer nanoparticles of the biodegradable and biocompatible polymer poly (lactic-glycolic) acid (PLGA), loaded with the drug pentoxifylline, the method for the synth...  
WO/2014/075203A1
The invention relates to a novel pharmaceutical formulation comprising polymer nanoparticles of the biodegradable and biocompatible polymer poly (lactic-glycolic) acid (PLGA), loaded with the drug pentoxifylline, the method for the synth...  
WO/2014/076702A1
A method of treating a disease selected from the group consisting of emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia, a neurodegenerative disorder, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischem...  
WO/2014/078314A1
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In...  
WO/2014/075570A1
Disclosed are a beautyberry total glycosides extract, a preparation method thereof and the use in preparing drugs for treating neurodegenerative diseases or skin diseases. The extract is prepared from the leaves of Callicarpa cathayana o...  
WO/2014/075387A1
Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in t...  
WO/2014/078454A1
Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of...  
WO/2014/077401A1
 Provided is a compound that has cholinergic muscarinic M1 receptor positive allosteric modulator activity and that is useful in the prevention and treatment of conditions such as Alzheimer's disease, schizophrenia, pain, and sleep dis...  
WO/2014/078645A1
Disclosed herein are heterocyclic compounds containing thiadiazole and/or pyridazine rings, as well as pharmaceutical preparations thereof. The compounds herein are further made known to be useful as glutaminase inhibitors with potential...  
WO/2014/076170A1
The present invention relates to new substituted pyrazolo[3,4- d]pyrimidine compounds of general formula (I) having a great affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof,...  
WO/2014/076235A1
The present invention relates to a composition for treating Fragile X syndrome in a subject in need thereof, wherein said composition comprises an effective amount of a modulator of a chloride transporter.  
WO/2014/078394A1
The current invention offers a method of treatment of aggression in a human subject suffering from ADHD, comprising: (a) determining the weight of the human subject; (b) calculating a dose of molindone such to achieve a plasma concentrat...  
WO/2014/078372A1
Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C...  
WO/2014/076643A1
A compound particularly for treating depression and anxiety, characterized in that it comprises the combination of at least 11 -keto-beta- boswellic acid (KBA) and acetyl-11-keto-beta-boswellic acid (AKBA). The patent also relates to the...  
WO/2014/075629A1
A method of extracting neural stem cells from a living subject, comprising the steps of introducing magnetic nanoparticles into the subject, targeting the neural stem cells with the magnetic nanoparticles to form magnetic nanoparticle-ta...  
WO/2014/075146A1
The present invention relates to novel macrocyclic compounds of Formula I and their use as novel therapeutic agents for example as novel compounds used in methods of preventing and/or treating a disease, condition or state in a subject a...  
WO/2014/074381A1
The subject invention provides a Laquinimod amine salt, which is laquinimod meglumine, laquinimod choline hydroxide, laquinimod L-lysine or laquinimod monoethanolamine.  
WO/2014/073889A1
The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-benzyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperatu...  
WO/2014/071507A1
The disclosure provides compositions containing preparations from plants of the family Marcgraviaceae and from plants of the family Platanaceae. The disclosure also provides methods and uses of plant preparations for treating anxiety, st...  
WO/2014/073450A1
The present invention addresses the problem of providing a drunkenness-relieving agent which can relieve the severity of a badly or heavily drunk state in heavy alcohol use. The means for solving the problem is the use of an insoluble co...  
WO/2014/074795A1
The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working densi...  
WO/2014/072261A1
The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.  
WO/2014/072881A1
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention...  
WO/2014/071449A1
The present disclosure teaches generally neuroprotection and in particular the use of non-hormonal neuroactive steroids to ameliorate inflammation of the central nervous system (CNS). More specifically, the present claims define methods ...  
WO/2014/072957A1
Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5 and m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly α7 subtype, its tautomeric forms, its stereoisomers, its pharmaceutically...  
WO/2014/073946A3
The invention relates to the use of betanidine and its derivatives, betalains and their derivatives, betalamic acid and its derivatives, including the spatial configurations thereof, for the production of a drug for the treatment, preven...  
WO/2014/074976A1
Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, de...  
WO/2014/072498A1
The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carboni trile derivatives having pharmacological activity formula (I) to processes of preparation of such compounds, to pharmaceutical compositions com...  
WO/2014/074592A1
The instant invention relates to seaweed extract compositions, processes for isolation, isolated active agents, and methods of treating disease, disorders and conditions in a subject, including, reactive oxygen species (ROS)- mediated di...  
WO/2014/071371A1
Disclosed herein are cocrystals of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, which is a prodrug of methyl hydrogen fumarate  
WO/2014/069667A1
An objection of the present invention is to provide an agent for preventing or improving decline in brain function such as decreased perception ability, decreased memory learning ability, decreased thinking ability, decreased concentrati...  
WO/2014/068988A1
The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which v...  
WO/2014/071134A1
In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embod...  
WO/2014/068372A1
The present invention relates to a pharmaceutical composition of tapentadol for parenteral administration which provides prolonged release of tapentadol. Present invention also relates to the process of preparation of pharmaceutical comp...  
WO/2014/071042A1
The present invention provides, inter alia, methods for identifying a candidate agent that may be effective to treat or ameliorate an effect of a neurodegenerative disease in a subject. These methods include: (a) contacting a wildtype ne...  
WO/2014/069626A1
Provided is a method for producing a compound represented by formula (I) (wherein R1 and R2 may be the same or different and each represents a hydrogen atom or the like, and Z represents an optionally substituted aryl group or the like) ...  
WO/2014/070038A1
The invention relates to the pharmaceutical industry and the field of medicine and can be used in the creation and administration of solid dosage forms having neuroprotective, antiamnesic, antioxidant, antihypoxic and anti-ischemic activ...  
WO/2014/071219A1
The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfec...  
WO/2014/067281A1
Disclosed is a tapentadol hydrochloride crystalline form C having high stability and having characteristic peaks at 14.627 (100%), 15.476 (20.7%), 16.710 (33.7%), 18.999 (48.3%), 20.479 (80.7%), 21.790 (27.9%), 25.110 (35.2%), 25.911 (36...  
WO/2014/071044A1
The invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R', R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are ...  
WO/2014/067038A1
Disclosed are target points for treating human ADSL deficiency, the target points comprising PAICS gene, mRNA of PAICS gene or PAICS protein. Use of PAICS gene, mRNA of PAICS gene or PAICS protein for treating human ADSL deficiency is al...  

Matches 501 - 550 out of 46,549